Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy

preview_player
Показать описание
Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who fail venetoclax-based salvage therapies, commenting on poor prognosis. Dr Zucenka reports that venetoclax re-initiation or low-dose cytarabine plus glasdegib may be possible options for patients in this subgroup. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Andrius Zucenka
  3. Institution: Vilnius University Hospital Santaros Klinikos
  4. Event: EHA 2021
  5. Format: Interview
  6. Subject: Acute Myeloid Leukemia
Рекомендации по теме
Outcomes and options 0:01:55

Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy

Outcomes and management 0:02:22

Outcomes and management of patients with R/R myeloma who progress on bispecific antibodies

Improving outcomes for 0:02:28

Improving outcomes for R/R DLBCL with polatuzumab vedotin

Long-term outcomes with 0:01:31

Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCL

Improving outcomes for 0:02:26

Improving outcomes for FLT3-mutated R/R AML

Improving outcomes for 0:01:06

Improving outcomes for patients with R/R myeloma

Factors to predict 0:04:49

Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy

Real-world outcomes of 0:03:23

Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy

Using AI to 0:01:57

Using AI to predict the outcomes of patients with R/R DLBCL treated with tisagenlecleucel

The impact of 0:02:58

The impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel

Management and outcomes 0:01:32

Management and outcomes of elderly patients with LBCL

Clinical outcomes of 0:01:47

Clinical outcomes of patients with R/R multiple myeloma listed for treatment with CAR-T therapy

Phase III KEYNOTE-204: 0:03:51

Phase III KEYNOTE-204: does prior therapy impact outcomes in R/R cHL?

Outcomes of patients 0:03:35

Outcomes of patients with DLBCL who relapse early following R-ICE chemoimmunotherapy

Inferior outcomes of 0:05:32

Inferior outcomes of European vs. US patients with R/R LBCL after CD19 CAR-T cell therapy

The impact of 0:03:46

The impact of cytogenetic risk on outcomes of haploidentical transplantation in R/R AML

Combining IMiDs and 0:06:16

Combining IMiDs and BiTEs or CAR T to improve outcomes for patients with R/R AML

Long-term ibrutinib outcomes 0:01:35

Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL

Using Health Economics 0:07:11

Using Health Economics And Outcomes Research In Epilepsy Treatment

MANTLE-FIRST results: outcomes 0:02:10

MANTLE-FIRST results: outcomes in R/R younger MCL by therapy type

Outcomes of patients 0:03:25

Outcomes of patients who are BCMA-exposed versus BCMA-naïve in penta-R/R myeloma

Long-term outcomes of 0:05:22

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

Selection of front-line 0:13:26

Selection of front-line MCL therapies for optimizing outcomes in young vs. old patients

How can we 1:03:16

How can we use biologics and surgery to get the best outcomes for patients with CRSwNP?